Operator
Ladies and gentlemen, thank you for standing by. Hello, and welcome to the conference call hosted by Dare Bioscience to review the company’s first quarter 2026 financial results and to provide a business update.
This call is being recorded. My name is King, and I will be your operator today.
With us today from Dare are Sabrina Martucci Johnson, President and Chief Executive Officer; and MarDee Haring-Layton, Chief Accounting Officer.
Ms. Haring-Layton, please proceed.
MarDee Haring-Layton
Chief Accounting Officer
Good afternoon, and welcome to the Dare Bioscience financial results and business update call for the quarter ended March 31, 2026.
Today, we will review our financial results, provide updates on our clinical pipeline and discuss the continued execution of our expanded business strategy. That strategy includes a dual path approach, commercializing proprietary formulations through 503B compounding while pursuing FDA approval, and advancing select solutions as branded consumer health products that do not require a prescription. In all cases, our goal is to bring innovative women’s health solutions to market as efficiently and quickly as possible.
I would like to remind you that today’s discussion will include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Any statements made during this call that are not statements of historical facts should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks
